MET and non-small cell lung carcinoma: While the development of secondary EGFR mutations [5], [26] and alternative survival signals from other growth receptor activations such as c-Met [28], [29] have been widely known for conferring acquired gefitinib resistance of NSCLC patients who express activating EGFR mutations, very few related studies have reported the use of wtEGFR-expressing cells as the study model [21].